Equities

Rua Bioscience Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RUA:NZC

Rua Bioscience Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NZD)0.035
  • Today's Change0.00 / 0.00%
  • Shares traded544.13k
  • 1 Year change+19.86%
  • Beta0.5709
Data delayed at least 20 minutes, as of Feb 15 2026 23:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Rua Bioscience Limited is a New Zealand-based medicinal cannabis company. The Company is principally engaged in the research and development, sale, and marketing of pharmaceutical products in Germany, Australia, and New Zealand. It focuses on areas such as Plant Discovery and Breeding, as well as the International Sales and Marketing of medicinal cannabis. The Company supplies Good Manufacturing Practice (GMP)-certified medicines to expanding markets, supported by international supply agreements in Europe and a partnership in Australia for GMP-certified products. The Company has also invested in its subsidiary, Rua Bioscience Australia Pty Ltd.

  • Revenue in NZD (TTM)1.51m
  • Net income in NZD-3.46m
  • Incorporated2017
  • Employees12.00
  • Location
    Rua Bioscience Ltd704 Te Araroa Road, RuatoriaGISBORNE 4083New ZealandNZL
  • Phone+64 63906938
  • Websitehttps://www.ruabio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vivimed Labs Ltd19.04m-4.46m11.23m586.00------0.5901-2.93-2.9312.54-5.780.11150.88321.171,776,860.00-2.60-9.00-4.80-13.9151.9327.65-23.29-35.170.6624-5.541.14---22.00-35.7129.67---47.43--
Onyx Biotec Ltd12.14m195.30k11.77m--30.501.1815.540.96961.161.1644.5030.180.78143.902.95--1.26--1.90--29.72--1.61--1.352.130.2233--15.26--36.31------
Rua Bioscience Ltd1.51m-3.46m11.86m12.00--1.64--7.85-0.0179-0.01790.00760.02130.20822.864.70125,940.00-47.59-34.67-58.60-37.9835.39---228.66-1,828.561.03-19.660.1412--1,660.58--74.81---76.72--
NUTEX Befektetesi Nyrt2.33k1.40m11.91m1.008.150.44318.485,104.351.781.780.002932.720.00008--1.57--4.953.344.963.34100.00--60,198.0034,081.60309.41--0.000.000.00-9.71147.43--11.94--
Odi Pharma AB (publ)1.66m-875.89k11.97m1.00--220.56--7.19-0.2851-0.28510.52660.0161.33--5.298,971,460.00-70.09-40.68-1,151.76-60.97-29.08---52.61-95.17---8.510.00---85.94---944.49------
Nuformix PLC0.00-1.47m12.16m3.00--6.86-----0.0004-0.00040.000.00040.00-------65.61---88.76----------------------82.08------
cbdMD Inc31.78m-7.24m12.19m42.00--0.8655--0.3835-3.92-3.924.770.81041.832.8318.96---19.44-48.27-44.42-54.9962.3763.95-10.63-85.601.20--0.00---1.50-14.4543.21---32.56--
Pharmesis International Ltd.16.22m1.99m12.47m--6.660.84475.460.76880.0450.0450.41410.35510.67072.953.16--7.54-0.920513.30-1.5235.7044.7111.25-1.650.790713.020.2089--48.2412.70266.96---28.88--
Data as of Feb 15 2026. Currency figures normalised to Rua Bioscience Ltd's reporting currency: New Zealand Dollar NZD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.